Cutaneous Squamous Cell Carcinoma
80
22
37
19
Key Insights
Highlights
Success Rate
68% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
11.3%
9 terminated out of 80 trials
67.9%
-18.7% vs benchmark
3%
2 trials in Phase 3/4
53%
10 of 19 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 19 completed trials
Clinical Trials (80)
A Study of IDP-001 in Advanced or Metastatic Solid Tumors
Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma
Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma
Study of Metabolic Changes in the Transformation Malignant Precancerous Skin Lesions
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma
A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer
Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer (cSCC)
Cutaneous Squamous Cell Carcinoma Staging Study
ctDNA in Cutaneous Squamous Cell Carcinoma
Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma
FLASH Radiotherapy for Skin Cancer
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
TIL Therapy in cSCC and MCC